Lubiprostone

Summary

Lubiprostone (CHEMBL1201134) is an approved small molecule (ATC A06AX03) targeting CLCN2; indicated across 5 conditions including irritable bowel syndrome and constipation disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A06AX03
• Targets: 1 (CLCN2)
• Indications: 5 conditions
• Clinical trials: 48
• Chemistry: 390.5 Da · C20H32F2O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201134
Name	Lubiprostone
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	157920
ATC	A06AX03
Molecular formula	C20H32F2O5
Molecular weight	390.5
InChIKey	WGFOBBZOWHGYQH-MXHNKVEKSA-N

SMILES: CCCCC([C@]1(CC[C@H]2[C@H](O1)CC(=O)[C@@H]2CCCCCCC(=O)O)O)(F)F

IUPAC name: 7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid

Also known as: Amitiza, Lubiprostona, Lubiprostone, Lubiprostone hemiketal, RU-0211, SPI-0211, LUBIPROSTONE, SID144206539, lubiprostone

Patent coverage: 954 distinct patent families (3,840 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CLCN2	ClC-2			0.1%	P51788

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): CLCN2.

Top Reactome pathways

1 total, by targets touching each:

Pathway	Targets	Genes
Stimuli-sensing channels	1	CLCN2

Dominant GO biological processes

GO term	Targets
chloride transport	1
phagocytosis, engulfment	1
stabilization of membrane potential	1
lung development	1
regulation of aldosterone biosynthetic process	1
positive regulation of oligodendrocyte differentiation	1
retina development in camera-type eye	1
regulation of resting membrane potential	1
cell differentiation involved in salivary gland development	1
cellular hypotonic response	1
acinar cell differentiation	1
regulation of membrane depolarization during action potential	1
monoatomic ion transport	1
monoatomic ion transmembrane transport	1
transmembrane transport	1

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
irritable bowel syndrome	4	MONDO:0005052	EFO:0000555
constipation disorder	4	MONDO:0002203	HP:0002019

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
HIV infectious disease	2	MONDO:0005109	EFO:0000764

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 48.

Phase distribution

Phase	Trials
PHASE3	21
PHASE4	11
Not specified	8
PHASE1	3
PHASE2/PHASE3	2
PHASE2	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00452335	PHASE4	COMPLETED	Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation
NCT00645801	PHASE4	COMPLETED	Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation
NCT00746395	PHASE4	COMPLETED	Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy
NCT00844831	PHASE4	COMPLETED	Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit
NCT00908076	PHASE4	COMPLETED	Amitiza in Constipation Associated With PD (Parkinson’s Disease)
NCT00953017	PHASE4	COMPLETED	A Trial Comparing Split-Dose Miralax With Amitiza Pretreatment Versus Dulcolax Pretreatment Versus Golytely for Bowel Cleansing Prior to Colonoscopy
NCT00953043	PHASE4	COMPLETED	Lubiprostone, Colonic Motility and Sensation
NCT01096290	PHASE4	TERMINATED	Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications
NCT01170039	PHASE4	COMPLETED	The Effectiveness of Lubiprostone in Constipated Diabetics
NCT01236534	PHASE4	COMPLETED	Lubiprostone in Patients With Multiple Sclerosis Associated Constipation
NCT01460225	PHASE4	COMPLETED	Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation
NCT07277907	PHASE3	RECRUITING	Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation
NCT00380250	PHASE3	COMPLETED	Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation
NCT00399542	PHASE3	COMPLETED	Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation
NCT00595946	PHASE3	COMPLETED	Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone
NCT00597428	PHASE3	COMPLETED	Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone
NCT00620061	PHASE3	COMPLETED	Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
NCT01298219	PHASE3	COMPLETED	Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)
NCT01324284	PHASE3	COMPLETED	Comparative Study of Lubiprostone and PEG Preparation Versus Conventional PEG Preparation for Colonoscopy
NCT01372423	PHASE3	COMPLETED	Evaluation of Clinical Equivalence Between Two Lubiprostone Products
NCT01447849	PHASE2/PHASE3	COMPLETED	Lubiprostone and Mucus Secretion in Patients With Chronic Constipation
NCT01469819	PHASE2/PHASE3	COMPLETED	Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation
NCT01674530	PHASE3	COMPLETED	Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation
NCT01993875	PHASE3	COMPLETED	Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
NCT02042183	PHASE3	COMPLETED	Lubiprostone in Children With Functional Constipation
NCT02138136	PHASE3	COMPLETED	Lubiprostone for Children With Constipation
NCT02481947	PHASE3	COMPLETED	A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults
NCT02651155	PHASE3	COMPLETED	Lubiprostone for the Treatment of Chronic Idiopathic Constipation
NCT02695719	PHASE3	COMPLETED	Lubiprostone for Treatment of Chronic Idiopathic Constipation
NCT02729909	PHASE3	COMPLETED	Lubiprostone for Chronic Idiopathic Constipation Treatment
NCT02766777	PHASE3	COMPLETED	Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation
NCT03097861	PHASE3	COMPLETED	Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo
NCT05144295	PHASE3	COMPLETED	Lubiprostone for Functional Constipation in the Under 18 Years Patients
NCT05768334	PHASE3	COMPLETED	Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease
NCT06543979	PHASE1/PHASE2	RECRUITING	Anorectal Manometery in Pediatric Chronic Refractory Constipation
NCT01839734	PHASE2	COMPLETED	Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy
NCT02544152	PHASE2	TERMINATED	Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome
NCT00934479	PHASE1	COMPLETED	Intestinal Microecology in Chronic Constipation
NCT01166789	PHASE1	COMPLETED	Lubiprostone Effects on Visceral Pain Sensitivity
NCT01190020	PHASE1	COMPLETED	Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.
NCT03720613	Not specified	RECRUITING	Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
NCT00611442	Not specified	COMPLETED	Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy
NCT00662363	Not specified	COMPLETED	Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation
NCT00669461	Not specified	TERMINATED	Lubiprostone as a Treatment for Constipation in Parkinson’s Disease
NCT00689026	Not specified	TERMINATED	Efficacy of Lubiprostone in Combination With Standard PEG Preparation
NCT00706004	Not specified	COMPLETED	Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis
NCT01085643	Not specified	COMPLETED	Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)
NCT01162863	Not specified	COMPLETED	Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).